CFB
NVCR icon

Cullen/Frost Bankers’s NovoCure NVCR Stock Holding History

Cullen/Frost Bankers’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9
Closed -$1K – 1170
2022
Q3 		$1K Buy
+9
New +$702 ﹤0.01% 1110
2021
Q4 		– Sell
-300
Closed -$35K – 1279
2021
Q3 		$35K Buy
+300
New +$45.4K ﹤0.01% 847
2020
Q4 		– Sell
-3
Closed – – 1148
2020
Q3 		$0 Buy
+3
New +$240 ﹤0.01% 1235

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cullen/Frost Bankers's NVCR Position: Q4 2022 in Review

Cullen/Frost Bankers sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 9 shares — an estimated $1K sold.

Cullen/Frost Bankers first reported a position in NVCR in Q3 2020 and held it in 3 quarters. The position peaked at $35K in Q3 2021. 305 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Cullen/Frost Bankers reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Cullen/Frost Bankers sold 9 NovoCure shares in Q4 2022, an estimated $1K.
  • Cullen/Frost Bankers first reported a position in NovoCure in Q3 2020 and held it in 3 quarters.
  • Cullen/Frost Bankers's NovoCure position peaked at $35K in Q3 2021.
  • 305 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Cullen/Frost Bankers's 13F filing for Q4 2022, filed 13 Feb 2023.